China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
China Pharma Holdings, Inc. (''China Pharma'') which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced that it has retained HC International, Inc. (HCI) to initiate a proactive and targeted investor relations campaign.
Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications.
HC International is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. HCI will leverage its recognized investment community relationships to help capitalize on China Pharma's key assets while helping management to articulate its accomplishments to date and its future growth opportunities. Additionally, the firm will help to extend China Pharma's market development, investor awareness and shareholder communications.
China Pharma, through its subsidiary, Hainan Helpson Bio-pharmaceutical Co., Ltd, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. The Company focuses on therapeutics for CNS, cardiovascular, cerebrovascular, wound recovery, and infectious diseases.
Its products are sold in more than 20 provinces, sovereignties, and autonomous regions through 16 sales offices and approximately 680 proxy agents in China. China Pharma generated revenues of $24.0 million and net income of $8.8 million in the first nine months of 2007, up 75.6% and 72.0%, respectively, from the same period of 2006.
"This is an exciting time for China Pharma Holdings, Inc. as we continue to expand our business,'' said Ms. Zhilin Li, CEO of China Pharma Holdings, Inc. "After careful review, we selected HC International to ensure that our shareholders and members of the investment community are properly informed of our growth strategy and competitive advantages, including our focus on addressing high mortality diseases in China which includes targeting specific patient populations.
The team at HC International is well respected and has a proven track record of representing many successful China based, US listed companies, including those operating in the Pharmaceutical Industry. We are confident they will help us to improve our overall communication capabilities, which includes delivering our story and subsequent milestones to a larger, targeted base of investors.''
"China Pharma is a very profitable pharmaceutical manufacturer in China that is well positioned to capitalize on its core strengths to address a large emerging market opportunity," said Matthew Hayden, President of HC International. "Given its strong management team, research and development expertise, and diverse product pipeline of potential new drugs, China Pharma presents an attractive opportunity for investors by possessing the necessary assets to build shareholder value over the long term.''
Source : money.cnn.com
Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications.
HC International is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. HCI will leverage its recognized investment community relationships to help capitalize on China Pharma's key assets while helping management to articulate its accomplishments to date and its future growth opportunities. Additionally, the firm will help to extend China Pharma's market development, investor awareness and shareholder communications.
China Pharma, through its subsidiary, Hainan Helpson Bio-pharmaceutical Co., Ltd, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. The Company focuses on therapeutics for CNS, cardiovascular, cerebrovascular, wound recovery, and infectious diseases.
Its products are sold in more than 20 provinces, sovereignties, and autonomous regions through 16 sales offices and approximately 680 proxy agents in China. China Pharma generated revenues of $24.0 million and net income of $8.8 million in the first nine months of 2007, up 75.6% and 72.0%, respectively, from the same period of 2006.
"This is an exciting time for China Pharma Holdings, Inc. as we continue to expand our business,'' said Ms. Zhilin Li, CEO of China Pharma Holdings, Inc. "After careful review, we selected HC International to ensure that our shareholders and members of the investment community are properly informed of our growth strategy and competitive advantages, including our focus on addressing high mortality diseases in China which includes targeting specific patient populations.
The team at HC International is well respected and has a proven track record of representing many successful China based, US listed companies, including those operating in the Pharmaceutical Industry. We are confident they will help us to improve our overall communication capabilities, which includes delivering our story and subsequent milestones to a larger, targeted base of investors.''
"China Pharma is a very profitable pharmaceutical manufacturer in China that is well positioned to capitalize on its core strengths to address a large emerging market opportunity," said Matthew Hayden, President of HC International. "Given its strong management team, research and development expertise, and diverse product pipeline of potential new drugs, China Pharma presents an attractive opportunity for investors by possessing the necessary assets to build shareholder value over the long term.''
Source : money.cnn.com
Posts
Post a Comment